摘要
[目的]探讨血清Her-2/neu蛋白在乳腺癌患者诊疗中的临床意义。[方法]应用化学发光法(chemiluminescence immunoassay,CLIA)对60例健康人、100例其他肿瘤患者和195例乳腺癌患者样本进行Her-2/neu蛋白检测。[结果]健康对照组、其他肿瘤对照组和乳腺癌组血清Her-2/neu浓度分别为10.3±1.7ng/ml、10.9±2.6ng/ml和23.7±38.8ng/ml,乳腺癌组浓度明显高于健康对照组(P=0.003)和其他肿瘤组(P=0.005)。Ⅰ～Ⅱ期乳腺癌血清Her-2/neu浓度明显低于Ⅲ～Ⅳ期,差异有统计学意义(P=0.001)。乳腺癌Her-2阴性、+、++和+++4组患者血清Her-2/neu蛋白浓度分别为32.3±56.2ng/ml、27.9±31.4ng/ml、17.7±29.2ng/ml和23.1±39.6ng/ml;血清Her-2/neu蛋白阳性率分别为26.67%、33.33%、11.11%和15.38%。转移性乳腺癌患者血清Her-2/neu检测结果与临床状态总体符合率为82.98%(39/47)。[结论]血清Her-2/neu蛋白水平与乳腺癌患者临床分期相关,化学发光法检测血清Her-2/neu蛋白在乳腺癌临床诊疗中有重要应用价值。
[ Purpose ] To investigate the clinical sinifieanc, e of serum Her-2/neu protein in the diagnosis and treatmenl for patienls with breast cancer. [Methods] Chemiluminescence immunoassay（CLIA） was used to detect serum Her-2/neu protein concentration from 60 cases of heahhy control, 195 cases of breast cancer and 100 cases of other cancers. [Resuhs] The serum Her-2/neu concentration in breast cancer group （23.7± 38.8ng/ml） was significantly higher than that in healthy control group（10.3±1.7ng/nd）（P=0.003） and other cancers group（10.9±2.6ng/ml）（P=0.005）. The serum Her-2/neu concentration in patients wilh breasl cancer （stageⅠ～Ⅱ） was significantly lower than that with stage v , with significant difference（P=0.001）. Based on the Her-2 im,nunohislochenfical results,the breast cancer patients were divided into 4 groups： negative, ＋, ＋＋, ＋＋＋. The serum tter-2/neu concentration were 32.3±56.2ng/ml, 27.9±31.4ng/ml, 17.7±29.2ng/ml and 23.1 ±39.6ng/ml respectively; and the positive rate of serum Her-2/neu protein was 26.67% ,33.33% , 11.11% and 15.38% respectively. The level of serum Her-2/neu was 82.98% accorded with clinical status in patients with metastatic breast cancer. [Conclusion] Serum Her-2/neu level in breast cancer patients is associated with clinical stage,and the CLIA Her-2/neu assay plays an important application value in diag- nosis,prognosis and treatment for breast cancer.
出处
《中国肿瘤》
CAS
2013年第4期295-298,共4页
China Cancer
